

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): December 15, 2021

**Akoya Biosciences, Inc.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-40344**  
(Commission  
File Number)

**47-5586242**  
(IRS Employer  
Identification No.)

**100 Campus Drive, 6th Floor**  
**Marlborough, MA**  
(Address of principal executive offices)

**01752**  
(Zip Code)

**(855) 896-8401**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common stock, par value \$0.00001 per share	AKYA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure.**

On December 15, 2021, Akoya Biosciences, Inc. (the “Company”) hosted an inaugural “Spatial Day” and presented slides which included a brief company overview (the “Company Overview”). A copy of the slides comprising the Company Overview is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company Overview may also be accessed under the “Investors” tab on the Company’s website at [www.akoyabiosciences.com](http://www.akoyabiosciences.com).

In accordance with General Instruction B.2 on Form 8-K, the information set forth in this Item 7.01 and the Company Overview slides, attached to this report as Exhibit 99.1, are “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

Please refer to Exhibit 99.1 for a discussion of certain forward-looking statements included therein and the risk and uncertainties related thereto.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit No.</b>	<b>Exhibit</b>
<a href="#">99.1</a> 104	<a href="#">Akoya Biosciences, Inc. Spatial Day 2021</a> Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 15, 2021

**Akoya Biosciences, Inc.**


By: /s/ Brian McKelligon  
Brian McKelligon  
Chief Executive Officer

---



# Spatial Day 2021

December 15, 2021



# Disclaimer

## Cautionary Note Regarding Forward-Looking Statements

This presentation includes express and implied "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "anticipate," "estimate," "expect," "intend," "may," "might," "plan," "project," "will," "would," "should," "could," "can," "predict," "potential," or the negative of these terms, and similar expressions intended to identify forward-looking statements. However, not all forward-looking statements contain these identifying words. These statements may relate to our strategic plans or objectives, revenues or earnings projections, or other financial items. By their nature, these statements are subject to numerous uncertainties, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. Moreover, neither we, nor any other person, assumes responsibility for the accuracy and completeness of these statements. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events.

## Market Industry Data

Projections, estimates, industry data and information contained in this presentation, including the Company's general expectations and market position and market opportunity, are based on information from third-party sources and management estimates. Although the Company believes that its third-party sources are reliable, the Company cannot guarantee the accuracy or completeness of its sources. The Company's estimates are derived from third-party sources, publicly available information, the Company's knowledge of its industry and assumptions based on such information and knowledge. The Company's estimates have not been verified by any independent source. All of the projections, estimates, market data and industry information used in this presentation involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such information. In addition, projections, estimates and assumptions relating to the Company's and its industry's future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including, but not limited to, those described above, that could cause future performance to differ materially from the Company's expressed projections, estimates and assumptions or those provided by third parties.



# Brian McKelligon

CEO, Akoya Biosciences

---



# Spatial Day Agenda

Welcome & Introduction

**Brian McKelligon**, CEO, Akoya Biosciences

---

Revolutionizing Our Understanding of Disease Biology

**Kai Kessenbrock, Ph.D.**, Principal Investigator, University of California, Irvine  
**Robert Schreiber, Ph.D.**, Professor of Pathology, Washington University, St. Louis

Q&A Roundtable – Hosted by **Niro Ramachandran, Ph.D.**, CBO, Akoya Biosciences

---

Changing the Standard of Care Using Spatial Biomarkers

**Carl Barrett, Ph.D.**, VP of Translational Medicine, AstraZeneca  
**Kurt Schalper, M.D., Ph.D.**, Professor of Pathology and Oncology, Yale University  
**Michael Montalto, Ph.D.**, CSO, PathAI

Q&A Roundtable – Hosted by **Pascal Bamford, Ph.D.**, SVP of R&D, Akoya Biosciences

---

The Future Direction of Akoya

**Niro Ramachandran, Ph.D.**, CBO, Akoya Biosciences

---

Closing Remarks

**Brian McKelligon**, CEO, Akoya Biosciences


---

Audience Q&A

---

# Akoya is Leading the Spatial Biology Revolution

Transforming discovery to clinical research



## Complete end-to-end solutions

with instruments, reagents, software, and services



## Consistent growth with recurring revenue

from global installed base of > 650



## Well-capitalized to drive portfolio expansion

through new products and commercial development



# Announcing New Spatial Biology Solutions

Key drivers for continued high growth



## **New spatial phenotyping solutions**

for increased multi-plexing and throughput




## **New multi-omic applications**

to enable spatial RNA analysis




## **Clinical advancements**


with proven robustness and workflow; continued investments and partnerships expand clinical impact



# Current Tissue Analysis Methods Migrate to Spatial





**Spatial Phenotyping**



**Understanding biomarkers in tissue context**

# Significant Unmet Medical Need in Immunotherapy

**JAMA** publication highlights spatial phenotyping as a superior approach<sup>1</sup>




<sup>1</sup> Lu S, Stein JE, Rimm DL, et al, JAMA Oncology 2019;5(8):1195-1204  
<sup>2</sup> Diggs and Hsueh Biomarker Research (2017) 5:12

# Immediate Opportunity in Discovery and Translational Markets with Clinical Rapidly Emerging



Meeting customer and market segment **requirements** drives market expansion

# Accelerating & Market Leading Publication Volume



\*As of December 15, 2021

# Akoya's Current Spatial Phenotyping Platforms



**Unbiased and high-parameter** via in-situ reagent delivery

**Robust and high-throughput** with industry-leading imaging technologies



**CODEX**



**Phenoptics**



# New Instrument and Workflow Solutions Drive Growth

Accelerating the discovery and validation of spatial biomarkers


Discovery

Translational

**Unbiased tissue analysis** at  
single cell, whole slide and high resolution

**Increased throughput and plex**  
delivering scale and speed

**Expanding menu** of applications  
and multi-omic capabilities



# Advancing Akoya's First Mover Advantage

Translating discoveries to the clinic and building the foundations for diagnostics



Taube J, et al, MITRE Study, Journal for Immunotherapy of Cancer, July 2021



# Akoya Biosciences - The Spatial Biology Company

Discovery

Translational

Clinical

Delivering **unbiased** spatial phenotyping, at a **speed** that enables routine large-scale studies, and establishing a **proven** capability to impact patient care in order to address a significant unmet medical needs.



Complete end-to-end solutions



New spatial phenotyping solutions and applications



Advancing clinical impact




Rapidly increasing high-impact publications




Consistent growth with recurring revenue



Well-capitalized to drive portfolio expansion







**Niro Ramachandran, Ph.D.**  
CBO, Akoya Biosciences

---





**Kai Kessenbrock, Ph.D.**  
Principal Investigator, University of California,  
Irvine

---





# Robert Schreiber, Ph.D.

Professor of Pathology, Washington University  
St. Louis

---

 Washington University in St. Louis

## Q&A Roundtable



**Niro Ramachandran, Ph.D.**  
CBO, Akoya Biosciences

---



**Kai Kessenbrock, Ph.D.**  
Principal Investigator, University of California,  
Irvine

---



**Robert Schreiber, Ph.D.**  
Professor of Pathology, Washington University,  
St. Louis

---





**Pascal Bamford, Ph.D.**  
SVP of R&D, Akoya Biosciences

---







## Carl Barrett, Ph.D.

VP of Oncology & Translational Science,  
AstraZeneca

---





**Kurt Schalper, M.D., Ph.D.**

Professor of Pathology & Oncology,  
Yale University

---

Yale





# Michael Montalto, Ph.D.

CSO, PathAI

---



## Q&A Roundtable



**Pascal Bamford, Ph.D.**  
SVP of R&D, Akoya Biosciences

---



**Carl Barrett, Ph.D.**  
VP of Oncology & Translational Medicine, AstraZeneca

---



**Kurt Schalper, M.D., Ph.D.**  
Professor of Pathology & Oncology, Yale University

---



**Michael Montalto, Ph.D.**  
CSO, PathAI

---



 **AKOYA**  
BIOSCIENCES®

---




## Niro Ramachandran, Ph.D.

CBO, Akoya Biosciences

---



# Spatial Phenotyping: Transforming Tissue Biology




Spatial phenotyping is **identifying every cell** within the tissue microenvironment

Spatial phenotyping requires every cell to be analyzed across the **entire tissue section**

Spatial phenotyping will reveal cell-cell interactions, **cellular neighborhoods**, **rare cell types** and predictive **spatial signatures**

# Spatial Applications Defined





# Suite of Solutions Provide Spatial Phenotyping at Any Scale

Discovery

Translational

Clinical

Simplest Cycling Platform

Highest Throughput Imaging Platform




CODEX




Phenoptics [Polaris]

PHENOCYCLER


PHENOIMAGER HT



# Spatial Biology 2.0



# Spatial Biology 2.0 Driven by Speed



From **10's** → **100's** of targets



Million cells in **Hours** → **Minutes**

# Introducing: The PhenoCycler-Fusion System

The **FASTEST, MULTI-OMIC, SINGLE-CELL** spatial biology solution



**SPATIAL BIOLOGY NOW HAS  
A PASSING LANE**


Map 1-million cells in just 10 minutes

Limited shipments in 2021  
**Full commercial launch in January 2022**




# World's First Integrated Spatial Biology Solution

Flexible & scalable to meet your needs of tomorrow



# A Solution For Every User : Any Target, Any Scale



Unbiased



PHENOCYCLER

Speed



PHENOIMAGER FUSION

Proven



PHENOIMAGER HT



Opal®



Protein



RNA

# Akoya's Technology Stack Will Transform the Pace of Spatial Biology Research







**Brian McKelligon**  
CEO, Akoya Biosciences

---



# Summary : Akoya Spatial Day 2021



**Unbiased**  
**PHENOCYCLER**  
High-parameter spatial multi-omics



**Speed**  
**PHENOIMAGER FUSION**  
Spatial phenotyping at scale



**Proven**  
**PHENOIMAGER HT**  
Advancing spatial phenotyping to the clinic



**Complete end-to-end solutions**  
with instruments, reagents, software, and services



**New spatial phenotyping solutions and applications**  
for increased throughput, multi-plexing and multi-omics



**Advancing clinical impact**  
with proven robustness, workflow and partnerships



**Rapidly increasing high-impact publications**  
with ~450 to date, 370 in '20 and '21



**Consistent growth with recurring revenue**  
from global installed base of > 650



**Well-capitalized to drive portfolio expansion**  
through new products and commercial development

